摘要
目的探讨玻璃体腔注射康柏西普治疗眼底血管性疾病的安全性和临床疗效。方法湿性老年性黄斑变性(w AMD)10例(11只眼),视网膜静脉阻塞(RVO)4例(4只眼),糖尿病视网膜病变(DR)4例(6只眼),中心性浆液性脉络膜视网膜病变1例(1只眼),慢性中心性渗出性脉络膜视网膜病变1例(1只眼),分别对其行玻璃体腔康柏西普(0.05 ml)注射治疗。随访时间为注射后1 d、2周、1个月、3个月,观察患者的最佳矫正视力、距黄斑中心凹1 mm直径范围内黄斑厚度值、眼压及不良反应。结果注射3个月后,w AMD组、RVO组及DR组的最佳矫正视力较注射前的变化没有统计学意义。中心性浆液性脉络膜视网膜病变1只眼最佳矫正视力由治疗前0.2恢复到0.4,中心性渗出性脉络膜视网膜病变1只眼,由治疗前0.3恢复到1.0,视力均明显提高。w AMD组:治疗前后黄斑部厚度差值(112.9±128.8)μm,RVO组:治疗前后黄斑病厚度差值(403.0±213.0)μm,DR组:治疗前后黄斑病厚差值(110.0±102.1)μm,差异均有统计学意义(P<0.05)。结论康柏西普对眼底血管性疾病治疗有效且安全。
Objective To evaluate the safety and the clinic efficacy of intravitreal conbercept injection for fundus vascular disease( wet age-related macular degeneration,w AMD and retinal vein obstruction,RVO and diabetic retinopathy,DR and central exudative chorioretinopathy,CEC and central serous chorioretinopathy,CSC). Methods Ten patients( 11eyes) with w AMD and four patients( 4 eyes) with RVO and four patients( 6 eyes) with DR and one patient( 1 eye) with CEC and one patient( 1 eye) with CSC were treated with an intravitreal injection of conbercept( 0. 05ml). Patients had follow- up on 1day,two weeks,1month and three months after injection. Outcome measures included pre and post-treatment changes in best-corrected visual acuity( BCVA),measurement of the central macular thickness( CMT) within diameter of1 mm at macula with optical coherence tomography( OCT) and intraocular pressure( IOP) and side effects. Results The changes of w AMD cases、RVO cases and DR cases in BCVA before injection and 3 months after injection showed no significant deference. The BCVA of patient with CEC whose visul aucity was 0. 2 before injection had improved to 0. 4 at 3 months after first injection. And the BCVA of patient with CSC increased from 0. 3 to 1. 0. The difference values of mean CMT before injection and 3 months after injection were( 112. 9 ± 128. 8) um of patients with w AMD,( 403. 0 ± 213. 0um) of patients with BRVO,( 110. 0 ± 102. 1) um of patients with DR and all had significant difference( P〈0. 05). All of the cases have no several side effect. Conclusions Intravitreal conbercept injection for Fundus vascular disease is effective with few side effect.
出处
《临床眼科杂志》
2016年第6期527-530,共4页
Journal of Clinical Ophthalmology
关键词
眼部血管性疾病
康柏西普
最佳矫正视力
黄斑部视网膜厚度
不良反应
Fundus vascular disease
Conbercept
Best-corrected visual acuity(BCVA)
The central macular thickness(CMT)
Side effects